Xadago
Active Ingredient(s): SafinamideFDA Approved: * March 21, 2017
Pharm Company: * NEWRON PHARMS US INC
Category: Parkinsons
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Xadago Overview
Safinamide (INN; brand name Xadago) is a drug used as an add-on treatment for Parkinson's disease during "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.[2][3][4] It was approved in Europe in February 2015,[2] in the United States in March 2017,[3] and in Canada in January 2019.[5] Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Ove...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Safinamide
Recent Xadago Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Safinamide
- Tablet: 100mg, 50mg
NDC Database Records for Xadago: (3 results)
Sorted by National Drug Code- 27505-110 Xadago 50 mg Oral Tablet, Film Coated by Us Worldmeds, LLC
- 27505-111 Xadago 100 mg Oral Tablet, Film Coated by Us Worldmeds, LLC
- 68621-0031 Xadago 100 mg Oral Tablet, Film Coated by Catalent Germany Schorndorf Gmbh